Bird Flu Market Size is valued at USD 1.41 Bn in 2023 and is predicted to reach USD 2.17 Bn by the year 2031 at a 5.82% CAGR during the forecast period for 2024-2031.
Bird flu is an infectious type virus that primarily affects birds which can cause severe disease in birds, leading to high mortality rates as well these viruses typically cause milder symptoms and may go unnoticed. The market related to bird flu infection spans pharmaceuticals, vaccines, diagnostics, and poultry industry management, driven by the need to prevent, diagnose, and treat avian influenza outbreaks. Demand for antiviral drugs, human vaccines against potential pandemic strains, and rapid early detection diagnostic tools are key components. The poultry industry, significantly affected by avian influenza, invests in biosecurity measures, surveillance, and vaccination to mitigate economic losses and trade restrictions. Public health preparedness, including government and international organization efforts in surveillance and emergency response, plays a crucial role.
Furthermore, because labour costs are low and raw materials are easily accessible in emerging nations, large firms are concentrating on moving their production facilities there. The market for bird flu treatments is anticipated to develop due to these causes. Additionally, it is anticipated that underdeveloped infrastructure in developing nations would restrict research and development capacities, hence impeding the expansion of the bird flu market. But rising government expenditure on infrastructure development and rising investment by big companies in product development are two things that should open up new doors for businesses in the target market.
Competitive Landscape
Some Major Key Players In The Bird Flu Market:
- Boehringer Ingelheim
- Ceva Santé Animale
- Zoetis
- Merck & Co.
- Ringpu Biology
- Yebio Bioengineering
- FATRO
- CAVAC
- ChengDu Tecbond
- QYH Biotech
- Elanco
- Phibro Animal Health
- Vetoquinol
- Hipra
- Venkys
- Anicon Labor GmbH
- Bioveta
- Lohmann Animal Health
- Biogenesis Bago
- Sanofi
- Hoffmann-La Roche Ltd.
- Mallinckrodt
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- AstraZeneca
- Johnson & Johnson Private Limited
- Bimeda, Inc.
- Phibro Animal Health Corporation
- Medion
- Other Prominent Players
Market Segmentation:
The bird flu market can be segmented based on Virus Type, Test Type, Treatment Type, and Animal Type. By Virus Type, the market is segmented into H5N1, H7N9, H5N6, H5N8, H10N8, H9N2, and Others. By Test Type, the market is segmented into PCR Tests, ELISA Tests, Hemagglutination Assays, Virus Isolation Tests, Next Generation Sequencing, and Others. By Treatment Type, the market is segmented into Vaccines, Antiviral Medication, Immunomodulators, and Others; by Animal Type, the market is segmented into Chickens, Ducks, Geese & Swans, Pigeons, Guinea Fowls, Turkeys, and Others.
Most Widespread Virus Type Segment Is H5N1.
The pathogenic influenza A virus subtype H5N1 is an emerging bird flu (Avian influenza) virus causing global concern as a potential pandemic threat. H5N1 is a large threat virus in Asia because of infected poultry due to low hygiene conditions and close quarters. It is easy for humans to be safe from bird infection, but human-to-human transmission is more difficult without prolonged contact. Public health officials believe avian flu strains may mutate to become easily transmissible between humans.
Most human cases of bird flu result from either handling dead infected birds or contact with infected fluids, which refers to being spread through contaminated surfaces and droppings. Most seasonal wild birds have only a mild form of the H5N1 strain; some domesticated birds, such as chickens or turkeys, are known to be infected. H5N1 can become much more deadly because the birds are often in close contact.
Segments PAPR Is The Most Widespread Prevention Method.
Along with proper infection control and personal protective equipment (PPE), the chance of infection by bird flu is low. Protecting the eyes, nose, mouth, and hands is crucial for prevention in poultry farms. Felicitous personal protective equipment includes aprons or coveralls, gloves, boots covers, and a head cover. Disposable PPE is recommended. An N-95 respirator with safety goggles is also part of the appropriate PPE. A fueled air purifying respirator (PAPR) with a helmet and face shield is also an option.
North America Has A Significant Revenue Share In The Global Bird Flu Market Region.
North America has taken the lead as the region of choice. Numerous companies producing avian influenza vaccines and diagnostics are in the United States. North America has taken the lead in epidemic planning and prevention strategies thanks to the large chicken markets in the United States and Canada. Tight food safety laws necessitate that commercial poultry farms implement biosecurity measures on a large scale. Major R&D expenditures have been made by top American pharmaceutical corporations to create avian flu vaccinations that are universally effective. This enables North America to combat new strains of avian influenza more effectively before they become widespread worldwide.
Recent Developments:
- In July 2023, The vaccination campaign scheduled to commence in October 2023 in France have chosen Boehringer Ingelheim, a German company, to supply the required quantity of 80 million doses of avian influenza vaccines. By commencing this campaign, France achieved the distinction of being the inaugural member state of the European Union to immunize poultry against avian influenza. Positive test results for vaccines manufactured in France by Ceva Animal Health and Boehringer Ingelheim were reported by officials of the Ministry of Agriculture last month.
Bird Flu Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 1.41 Bn |
|
Revenue Forecast In 2031 |
USD 2.17 Bn |
|
Growth Rate CAGR |
CAGR of 5.82 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Virus Type, Test Type, Treatment Type, and Animal Type. |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Boehringer Ingelheim, Ceva Santé Animale, Zoetis, Merck & Co., Ringpu Biology, Yebio Bioengineering, FATRO, CAVAC, ChengDu Tecbond, QYH Biotech, Elanco, Phibro Animal Health, Vetoquinol, Hipra, Venkys, Anicon Labor GmbH, Medion Farma Jaya, Bioveta, Lohmann Animal Health and Biogenesis Bago, Sanofi, F. Hoffmann-La Roche Ltd., Mallinckrodt, Elanco, GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, AstraZeneca, Johnson & Johnson Private Limited, Bimeda, Inc., Phibro Animal Health Corporation, HIPRA, Medion |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
